Sensei Biotherapeutics Inks $30M in Series B

Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, announced the successful closing of a $30 million Series B financing. The financing was co-led by existing investor Apeiron Investment Group and new investor Catalio Capital Management. Additional investments included new investors Pura Vida Investments and several international family offices, as well as existing investors Cambrian Biopharma, Moore Strategic Ventures, Steve Jurvetson's Future Ventures, and Presight Capital.

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary phage-based platform, ImmunoPhage, that enables the rapid generation of immune activating agents that fully engage the immune system. Using its proprietary ImmunoPhage platform, Sensei is developing a library of ImmunoPhage called Phortress targeting multiple tumor associated antigens to treat patients using a personalized yet off the shelf cocktail approach.